Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18166743 | MANNOSE CONJUGATED CHITOSAN-BASED INFLUENZA NANOVACCINE FORMULATIONS AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 17760180 | POLYPEPTIDES AND THEIR USE | Non-Final OA | University of Washington |
| 18076315 | OMICRON SARS-COV-2 ASSAY | Non-Final OA | Board of Regents, The University of Texas System |
| 18403028 | SITE-SPECIFIC ANTIBODY-DRUG GLYCONJUGATES AND METHODS | Final Rejection | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. |
| 18747563 | Antibodies to Andes Hantavirus, and Methods for Using Same | Final Rejection | Universidad De Concepcion |
| 18656948 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS | Final Rejection | INOVIO PHARMACEUTICALS, INC. |
| 18393160 | HUMAN HERPESVIRUS IMMUNOTHERAPY | Final Rejection | The Council of the Queensland Institute of Medical Research |
| 17723271 | RNA SEQUENCING TO DIAGNOSE SEPSIS AND OTHER DISEASES AND CONDITIONS | Non-Final OA | Rhode Island Hospital |
| 18067358 | EFFICIENT VACCINE | Final Rejection | VLP Therapeutics Japan, INC. |
| 16974123 | Localized activation of virus replicatio boosts herpesvirus-vectored vaccines | Non-Final OA | HSF Pharmaceuticals SA |
| 17786124 | TREATMENT OF HEPATIC AND CARDIOVASCULAR DISORDERS | Final Rejection | UNIVERSITÉ PAUL SABATIER TOULOUSE III |
| 17824702 | METHOD OF BREATH SCREENING OF VIRAL INFECTION | Final Rejection | ANIKA STERILIS PRIVATE LIMITED |
| 17260041 | METHODS FOR GENERATING BROADLY REACTIVE, PAN-EPITOPIC IMMUNOGENS, COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | University of Georgia Research Foundation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy